Medical News

RSS

Dimera granted peripheral artery disease patent

The U.S. Patent and Trade Office (USPTO) plans to announce patent award approval on August 11 to Dimera Incorporated for treatment of symptoms of Peripheral Arterial Disease (PAD), which is alternatively known as Peripheral Vascular Disease (PVD).

12 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Oxygen treatment may speed memory loss associated with Alzheimer's

A 65-year-old women goes into the hospital for routine hip surgery. Six months later, she develops memory loss and is later diagnosed with Alzheimer's Disease. Just a coincidence? Researchers at the University of South Florida and Vanderbilt University don't think so. They suspect that the culprit precipitating Alzheimer's disease in the elderly women may be a routine administration of high concentrations of oxygen for several hours during, or following, surgery - a hypothesis borne out in a recent animal model study.

12 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

An examination of the social impact of armed conflict and militarization

New research out of the University of Cincinnati is a rare examination of the social impact of armed conflict and militarization. Steve Carlton-Ford, a UC associate professor of sociology, presented the findings Aug. 11 at the 104th annual meeting of the American Sociological Association (ASA) in San Francisco.

12 Aug 2009

Potential new treatment for drug resistant brain tumors

Dr. Karen Newell, Ph. D., the lead researcher for bio technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th Annual Aspen Symposium on Brain Tumor Immuno- and Stem Cell Therapy. Her presentation will highlight the potential for combining chemotherapy with compounds that interfere with the ability of brain tumor cells to generate the energy needed to repair chemotherapy induced DNA damage.

12 Aug 2009

Alcoholics display abnormal brain activity when processing facial expressions

Researchers from Boston University School of Medicine (BUSM) have found that individuals who have a long history of alcoholism, but who have been abstinent for at least a month up to many years, showed abnormal brain activity when looking at facial expressions of others.

12 Aug 2009

Education impacts cognitive function in Alzheimer's disease

Researchers at the Department of Psychiatry, Klinikum rechts der Isar, Technische Universität München, investigated the effects of formal education on the symptoms of Alzheimer's disease. They were able to show that education diminishes the impact of Alzheimer's disease on cognition even if a manifest brain volume loss has already occurred.

12 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

New treatment for oxygen-starved newborns

Until now immediate cooling of the newborn infant was the only treatment that could possibly prevent brain damage following oxygen deprivation during delivery. New research findings from the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital, Sweden, in collaboration with Zhengzhou University in China, open up the possibility of a new and effective treatment that can be started as late as two days after birth.

12 Aug 2009

Retrovirox receives another NIH grant for novel inhibitors of HIV entry

RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.

12 Aug 2009

New tool for virtual surgery simulates blood flow - helps plan child's delicate heart surgery

Researchers at the Georgia Institute of Technology, collaborating with pediatric cardiologists and surgeons at The Children's Hospital of Philadelphia, have developed a tool for virtual surgery that allows heart surgeons to view the predicted effects of different surgical approaches. By manipulating three-dimensional cardiac magnetic resonance images of a patient's specific anatomy, physicians can compare how alternative approaches affect blood flow and expected outcomes, and can select the best approach for each patient before entering the operating room.

12 Aug 2009

Ranbaxy receives approval to market Sumatriptan Succinate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base).

12 Aug 2009

Neoprobe announces Q2 financials

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.

12 Aug 2009

Alticor and Metagenics enters into joint venture agreement

Alticor and Metagenics today announced that they have entered into a joint venture agreement. Under the terms of the agreement, Alticor will obtain a substantial ownership interest in Metagenics, and the current Metagenics shareholders will continue to retain a significant interest in the company. The agreement is subject to customary closing conditions, including approval by Metagenics shareholders and antitrust clearance.

12 Aug 2009

When issues at home interfere with work, sick days increase

Employees who feel that issues with home and family life are interfering with their work take more sick leave, more often, according to a study in the August Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

12 Aug 2009

Scientists discover how new drug kills roundworms

A PLoS Neglected Tropical Diseases study found how a new drug developed by scientists in China effectively kills roundworms – "a parasite that lurks in the intestines and which affects nearly two billion people in tropical countries," Reuters reports. "Roundworms are particularly harmful to children and pregnant women," Reuters writes.

12 Aug 2009

Aspirin improves survival after colorectal cancer diagnosis

Men and women who were diagnosed with colorectal cancer and began regular use of aspirin had a lower risk of overall and colorectal cancer death compared to patients not using aspirin, according to a study in the August 12 issue of JAMA.

11 Aug 2009

Shwarzenegger’s cuts to HIV/AIDS programs to be protested

AIDS Healthcare Foundation (AHF), the nation’s largest non-profit HIV/AIDS healthcare provider, is joining a broad-based coalition of AIDS advocates and patients to protest draconian budget cuts that were blue lined out of the budget by California Governor Arnold Schwarzenegger and that will jeopardize the public health by eliminating the vast majority of funding for AIDS prevention, care and treatment.

11 Aug 2009

Labopharm submits response to FDA for formulation of the antidepressant trazodone

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has submitted its response to the U.S. Food and Drug Administration's (FDA) complete response letter regarding the Company's novel formulation of the antidepressant trazodone.

11 Aug 2009